2seventy bio, Inc.
2seventybio.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2025 10-Q, filed May 7, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Aug 14, 2025.
10-Q for Q1 FY2025, filed May 7, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Commercializes Abecma, a cell therapy for multiple myeloma patients, with Bristol Myers Squibb.
10-K for FY2024, filed Mar 25, 2025We are a cell therapy company focused, together with our partner, BMS, on the commercialization and delivery of Abecma (idecabtagene…View ↗
We work closely with our partner, BMS, to manufacture, sell, and deliver Abecma to U.S. multiple myeloma patients.View ↗
Abecma and our collaboration with BMS.In March 2021, Abecma was initially approved by the FDA in the United States for the treatment of…View ↗
How Did They Make Money?
The company earns revenue through its BMS collaboration: it shares profits and losses from U.S. Abecma sales, and receives service payments for work such as ex-U.S. support; its share of U.S. profits or losses is recorded when BMS makes the sales and incurs related costs.
10-K for FY2024, filed Mar 25, 2025To date, the Company’s service revenue has primarily been generated from the elements of its collaboration arrangements with BMS and Novo…View ↗
Year Ended December 31, 2024 2023 ide-cel ex-U.S. service revenue from BMS $ 10,611 $ 14,751 Service revenue from December 2021 agreement…View ↗
Year Ended December 31, 2024 2023 U.S. Abecma collaboration with BMS $ 15,048 $ 50,010 Collaboration with Regeneron 4,696 21,591 Total…View ↗
Where the collaborator is the principal in the product sales, the Company recognizes its share of any profits or losses, representing net…View ↗
$37.9M
-
10-K for FY2024, filed Mar 26, 2025
$37.9M ↗
Who Were Their Customers?
BMS is the company’s collaboration partner for Abecma in the United States and for ex-U.S. service work; the filing also reports service revenue from Novo and other sources.
10-K for FY2024, filed Mar 25, 2025To date, the Company’s service revenue has primarily been generated from the elements of its collaboration arrangements with BMS and Novo…View ↗
Year Ended December 31, 2024 2023 ide-cel ex-U.S. service revenue from BMS $ 10,611 $ 14,751 Service revenue from December 2021 agreement…View ↗
To date, the Company’s collaborative arrangement revenue has been generated from its collaboration arrangements with BMS and Regeneron, as…View ↗
Did Revenues Turn Into Profits?
No. It lost $57.2M in FY2024.
10-K for FY2024, filed Mar 26, 2025
−$115.4MView ↗
10-K for FY2024, filed Mar 26, 2025
−$57.2MView ↗
10-K for FY2024, filed Mar 26, 2025
−$85.7MView ↗
How Were They Changing?
-
May 13, 2025
Bristol Myers Squibb completed its acquisition of 2seventy bio
The company became a wholly owned subsidiary of Bristol Myers Squibb, and its shares were removed from Nasdaq.
Sources
8-K, filed May 13, 2025
On May 13, 2025 2seventy bio (i) notified The Nasdaq Global Market (“Nasdaq”) of the consummation of the Merger and (ii) requested that…View ↗
Shrank. Revenue fell 85% in 4 years, from $248.1M in FY2020 to $37.9M in FY2024, about 37% a year.
From broad pipeline to Abecma
The older report described multiple cancer programs and a platform for developing engineered cell therapies. The latest report centers the business on Abecma, after selling solid tumor, oncology and autoimmune programs to Regeneron and the megaTAL hemophilia program to Novo.
10-K for FY2021, filed Mar 22, 2022 10-K for FY2024, filed Mar 25, 2025
Who Did They Compete With?
Competes with Janssen, Legend Biotech, Arcellx, Kite, BMS, Allogene Therapeutics, Poseida, Caribou, Pfizer, Regeneron, and GSK
10-K for FY2024, filed Mar 25, 2025The current standard of care for multiple myeloma includes IMiDs (e.g., thalidomide, lenalidomide, pomalidomide), proteasome inhibitors…View ↗
Loading...
